CONTENT PROVIDED FOR SHAREHOLDERS, INVESTORS, AND OTHER CAPITAL MARKET PARTICIPANTS ONLY
The following documents are specifically for shareholders, investors, and other capital market participants. This webpage is not intended for other members of the general public.
If you are not a shareholder, investor, or other capital market participant, please return to UCB's homepage.
Zilucoplan
Presentations, Abstracts, Posters
AANEM 2022
- Efficacy and safety of zilucoplan in MG: responder analysis from the randomized Phase 3 RAISE trial
- Safety and tolerability of zilucplan in RAISE XT: a multicenter, OLE extension study in patients with gMG
- QoL outcomes in RAISE: a double-blind randomized, placebo-controlled study of zilucplan in gMG